Market Mover: Evelo (EVLO) Climbs at Midday June 22

Equities Staff  |

Evelo Biosciences Inc (NASDAQ: EVLO) shares climbed 15.85%, or $0.29 per share, as on 11:54:33 est today. Opening the day at $1.81, 692,164 shares of Evelo have traded hands and the stock has traded between $2.31 and $1.81.  

Already the company has a YTD change of 69.85%.

Evelo expects its next earnings on 2022-07-28.

For technical charts, analysis, and more on Evelo visit the company profile.

About Evelo Biosciences Inc

Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company's first product candidates are pharmaceutical preparations of single strains of microbes selected for the potential to offer defined pharmacological properties. Evelo's therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.

To get more information on Evelo Biosciences Inc and to follow the company's latest updates, you can visit the company's profile page here: Evelo Biosciences Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade



Market Movers

Sponsored Financial Content